Annexin A

LCKLSL hydrochloride is an AnxA2 inhibitor with potential anti-angiogenic activity and inhibits the development of EAE.

Amcinonide (CL-34699) is a Corticosteroid. The mechanism of action of amcinonide is as a Corticosteroid Hormone Receptor Agonist.

PY-60 can effectively activate YAP transcriptional activity against annexin A2 (ANXA2).Cost-effective and quality-assured.

SIN-1 chloride is a moxidomine metabolite with vasodilatory, anti-platelet, and antianginal effects, reducing myocardial ischemia-related damage.

Lincydomine relaxes smooth muscles, treats unstable angina, and opens human and guinea pig respiratory tracts.

LCKLSL, an N-terminal hexapeptide, inhibits AnxA2 and tPA binding, reduces plasmin, and exhibits anti-angiogenic effects.

ANXA3 degrader 1 (Compound 18a5) is a highly selective ANXA3 degrader with activity against cancer cells. It demonstrates significant inhibitory effects in a triple-negative breast cancer (TNBC) tumor xenograft model, with a tumor growth inhibition (TGI) rate of 96%.

LCKLSL acetate is a potent AnxA2 inhibitor, blocking tPA binding and plasmin production, with anti-angiogenic effects.

A11 (ANXA1-derived 11 amino acid–long peptide) serves as an inhibitor of the ANXA1-EphA2 interaction, reducing ANXA1 attachment to EphA2 while promoting the association of Cbl (an E3 ubiquitin ligase of EphA2) with EphA2. This peptide also effectively lowers EphA2 levels, greatly enhances EphA2 ubiquitination, and stimulates EphA2 internalization along with the colocalization of EphA2 and Cbl in nasopharyngeal carcinoma (NPC) cells. Moreover, A11 curtails NPC cell proliferation, migration, and invasion, and it suppresses angiogenesis.

A2ti-1 is an annexin A2/S100A10 heterotetramer (A2t) inhibitor that inhibits Src activation and can be used to study human papillomavirus type 16 infection.

A2ti-2: selective A2/S100A10 inhibitor, IC50 230 μM, with antiviral action against HPV16.

ABO acts as an annexin A7 modulator, specifically binding to Thr286 to inhibit its phosphorylation on threonine (not on serine or tyrosine) residues within human umbilical vein endothelial cells (HUVECs). This compound furthers the annexin A7 interaction with the EF-hand protein GCA, leading to reduced GCA phosphorylation, lowered intracellular calcium levels, and enhanced autophagy in COS-7 cells. Moreover, ABO lessens phosphorylation of the microtubule-associated protein 1 light chain (LC3) in HUVECs and impedes the upregulation of phosphatidylcholine-specific phospholipase C (PC-PLC) due to oxidized low-density lipoprotein in vascular endothelial cells (VECs). In animal models, specifically apoE-/- mice on a Western diet, administration of ABO (50 or 100 mg/kg per day) has been shown to decrease PC-PLC expression, promote autophagy, and reduce apoptosis, lipid accumulation, and the extent of atherosclerotic plaques in the aortic endothelium.

PY-PAP is a photoactivatable affinity probe, derived from PY-60. It retains its cellular function of activating YAP transcription. In 293A cells, PY-PAP can label cathepsin D (CTSD) and annexin A2 (ANXA2) through UV crosslinking and click reactions. PY-PAP played a crucial role in identifying ANXA2 as a specific target of PY-60.

CI-936 (MRS-3310) is an orally active A2 agonist with a binding affinity of 25 nM. In preclinical studies, it has demonstrated potent and selective effects, indicating potential antipsychotic efficacy. Additionally, CI-936 inhibits exploratory behavior in mice.

(R)-SL18 is a degrader of ANXA3 that facilitates its breakdown via ubiquitination. This compound can inhibit the proliferation, migration, invasion, and colony formation of breast cancer cells, while also inducing apoptosis. (R)-SL18 is applicable for research in triple-negative breast cancer.